PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March.

See the rest here:
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled

Go here to see the original:
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in March.

Read the original:
CytomX Therapeutics to Present at Upcoming March Investor Conferences

Highlights:

Read more here:
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in...

Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23

View original post here:
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET.

Visit link:
Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in nonalcoholic steatohepatitis (NASH) and viral diseases, today announced that it will report the Company’s fourth quarter 2022 financial results on Thursday, March 9, 2023 after the close of the U.S. financial markets.

Excerpt from:
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023

1Includes net product sales reported by Adamas Pharmaceuticals prior to the acquisition of Adamas by Supernus Pharmaceuticals in November 2021.

Read more from the original source:
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.

Read this article:
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET.

Visit link:
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2022 before the market opens on March 9, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

More:
Harvard Bioscience Schedules Fourth Quarter 2022 Earnings Conference Call for March 9, 2023 at 8:00 AM ET 

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its cash position as of December 31, 2022 and revenues for 2022. 1 2

Original post:
GENFIT Announces Revenues and Cash Position as of December 31, 2022

EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Atlas Global Brands Inc. (“Atlas Global” or the “Company”) (CSE: ATL), a cannabis company with expertise across the cannabis value chain, is pleased to announce the appointment of BDO Canada LLP (“BDO”) as its new external auditor effective February 28, 2023 until the close of the next annual general meeting of shareholders.

Read the original:
Atlas Global Announces Change of Auditor and Year End

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a Novel Immuno-Oncology (IO) panel discussion at the Cowen 43rd Annual Health Care Conference taking place at the Marriott Copley Place in Boston, MA.

More here:
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

NEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET

Continue reading here:
MDxHealth to Participate in 43rd Annual Cowen Healthcare Conference

Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time

See more here:
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

See the article here:
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023

Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13

Excerpt from:
Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

UV, HEV protection for individuals at high risk of photoageing and skin cancer

Visit link:
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care

Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial

See the rest here:
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica